Healthcare solutions provider Solventum (NYSE:SOLV) reported Q3 CY2025 results , but sales were flat year on year at $2.10 billion. Its non-GAAP profit of $1.50 per share was 4.7% above analysts’ ...

7 analysts have shared their evaluations of Solventum (NYSE:SOLV) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...

Solventum, Minnesota’s newest Fortune 500 company, is finding its footing after starting its first full year of operations on shakier ground. The 3M spinoff commenced 2025 with a deflated stock, which ...

Solventum's main strategic priority is to repay debt following its separation from 3M. The business has consistently underperformed in its end markets, and a turnaround will take time. 3M appears to ...

Solventum, the recently spun off healthcare arm of 3M, faces challenges in value creation due to stagnant growth, heavy debt burden, and entanglement with its former parent. The company's revenue ...

It’s been almost a year since Solventum spun off as a separate business from 3M. Now, Solventum is orchestrating a spinoff of its own. On Tuesday, Solventum announced that it has lined up a deal to ...